Compare · INSM vs JNJ
INSM vs JNJ
Side-by-side comparison of Insmed Incorporated (INSM) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INSM and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $560.33B, about 27.4x INSM ($20.42B).
- Over the past year, INSM is up 33.2% and JNJ is up 49.9% - JNJ leads by 16.7 points.
- INSM has been more active in the news (9 items in the past 4 weeks vs 7 for JNJ).
- Both have 25 recent analyst ratings on file.
- Company
- Insmed Incorporated
- Johnson & Johnson
- Price
- $94.15-10.25%
- $232.71+1.95%
- Market cap
- $20.42B
- $560.33B
- 1M return
- -31.24%
- +3.67%
- 1Y return
- +33.21%
- +49.92%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 9
- 7
- Recent ratings
- 25
- 25
Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest INSM
- Chief Operating Officer Adsett Roger sold $242,380 worth of shares (2,370 units at $102.27), decreasing direct ownership by 2% to 98,603 units (SEC Form 4) (tax liability)
- Chief Financial Officer Bonstein Sara sold $245,857 worth of shares (2,404 units at $102.27), decreasing direct ownership by 3% to 69,082 units (SEC Form 4) (tax withholding)
- Chief Legal Officer Smith Michael Alexander sold $220,801 worth of shares (2,159 units at $102.27), decreasing direct ownership by 5% to 39,454 units (SEC Form 4) (tax liability)
- Chief Medical Officer Flammer Martina M.D. sold $455,248 worth of shares (4,424 units at $102.90) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 60,486 units (SEC Form 4) to satisfy withholding obligation
- Chair and CEO Lewis William sold $777,763 worth of shares (7,605 units at $102.27), decreasing direct ownership by 3% to 265,432 units (SEC Form 4) (for tax liability)
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
- Chief Legal Officer Smith Michael Alexander sold $666,982 worth of shares (6,149 units at $108.47) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 41,613 units (SEC Form 4)
- Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $2,718,224 worth of shares (25,564 units at $106.33) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 273,037 units (SEC Form 4)
- SEC Form S-3ASR filed by Insmed Incorporated
Latest JNJ
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Johnson & Johnson upgraded by Leerink Partners with a new price target